



Organisation
of European
Cancer Institutes

In collaboration with



FUNDACIÓN
INSTITUTO VALENCIANO
DE ONCOLOGÍA

Oncology Days

ECI 44

**PROMOTING INNOVATION
AND QUALITY FOR PATIENTS**

VALENCIA 2022

**GENERAL ASSEMBLY
AND
SCIENTIFIC CONFERENCES**

June 15th - 17th 2022

With the kind support of



DRIVE THE FUTURE IN COMPREHENSIVE CANCER CARE

FINAL
PROGRAMME

Welcome OECI Oncology Days 2022

The EU Strategy for smart, sustainable and inclusive growth set a strategic alliance between the Research and Innovation Framework Programme and the Health Programme as one of its main tools to fight cancer.

As a result, a new way to see interactions among the relevant stakeholders are necessary to improve future policy actions in the area of cancer with the main objectives to optimise cancer prevention, diagnosis and treatment, and ensure equitable access to care across Europe, especially in economically deprived areas.

Strategic alliances among countries are paramount to decrease barriers of access to high quality care, and this is the spirit that gave rise to a joint attempt of the DG Health & Food Safety and DG Research & Innovation to create a European cancer centres infrastructure. The same initiatives paves the way to supporting Member States to build a national infrastructure there, where they lack one.

The stakes are high and cooperation between health and research & innovation programmes has always been complex. Hopefully, this time round, the wisdom collected from the entire cancer community will push Europe into the right direction, one that will help us take bold actions, reduce the incidence and reverse the frightening trends in cancer today.

The projected outcomes look encouraging but, in spite of the extraordinary financial efforts undertaken at European level, the way to get there is arduous.

In fact, beyond the ambitious goals set by the EC, we must still take into account the fact the COVID-19 pandemic has severely impacted cancer care, disrupting prevention and treatment, delaying diagnosis, and affecting access to cancer care infrastructures. Since the beginning of the pandemic, the number of cancer diagnoses has decreased, foreshadowing a future increase in cases.

By 2040, the number of people newly diagnosed with cancer every year will have increased from 4.2 to 5.2 million. On top of that, the rising costs of cancer treatments, along with their ever-increasing complexity constitute a great burden on our health systems. Studies on RWD to produce RWE may help to reduce ineffective treatments, thus preventing health systems from collapsing.

So how do we get there? We must certainly hone our best practices, even if, in this initial phase, this occurs at a local level. We also ought to place greater attention onto the quality assessment of both our health systems in their entirety and the environment where cancer patients receive their treatments. In order to do so, we must reach consensus on a European quality accreditation system based on unified standards agreed upon the entire cancer community. I am not referring here to a mere assessment of quality & quantity metrics, but to a pragmatic system capable of reaching concrete targets, singling out shortages and granting improvement.

The final goal is to unify the global approach to the cancer patient. We need to shape improved models of healthcare facilities and thus achieve a single European network that implements unified standards.

The Cancer Mission has brought forward ambitious R&I goals in answer to real demands: Europe is home to a 1/10 of the world population; nonetheless, 1/4 of the world's cancer

patients live here, and figures are expected to go up by 24% by 2035, thus overcoming cardiovascular diseases. This expected rise requires enhanced budget, with an increase in public expenditure of some €100 billion.

We look at OECI and its 110 Members as to an mature embryo of a European cancer network. This is why I hope that all the efforts undertaken to participate to the challenges put forward by the EC will yield the expected and long-awaited results.

We would like to extend our gratitude towards all those who voluntarily contributed to all our initiatives which will be presented here, in Valencia, as part of an agenda that includes some of the most relevant topics that the cancer community is facing today.

We would also like to thank the Fundacion IVO, an institute of excellence and innovation founded in 1976 by Professor Antonio Llombart Rodriguez. Fundacion IVO is one of the first cancer centres to be established here, in Spain, as well as a well-recognised entity both at a national and international level. IVO is also the first Spanish centre to be certified with the OECI Accreditation and Designation Programme.

Since 1996, IVO has been led by the trustworthy hands of Prof. Antonio Llombart Bosch, who has also been a valuable OECI Treasurer, Board Member and organiser of the OECI 2000 Event.

Today, the General Director of Fondacion IVO, Prof. Manuel Llombart Fuertes is the OECI Treasurer and it is thanks to his collaboration that Oncology Days 2022 are hosted in Valencia, a fantastic venue, and a great city of science and culture.



Thierry Philip
OECI President



Giovanni Apolone
OECI President Elect

THE 44TH EDITION OF THE OECI: WELCOME TO VALENCIA

The 44th edition of the annual meeting of the OECI, is held this year in Valencia, Spain, from June 15 to 17.

It is a great honor for the Fundación Instituto Valenciano de Oncología (IVO) the decision of the OECI to choose Valencia as the place to celebrate the “**OECI Oncology Days 2022**” and to designate the IVO as the organizer of this event. We want to remember that our institution already hosted the Oncology Days in 2000. Since then, both the OECI and the IVO have developed important work in the field of Oncology in Europe and Spain, significantly expanding their influence in all areas of the fight against this disease.

At present, with nearly 50 years of existence, the Valencian Institute of Oncology is a monographic center specialized in comprehensive care for cancer patients. The IVO, a center accredited by the OECI, is a private, non-profit organization, whose assets and resources are entirely allocated to the fight against cancer in all its aspects: prevention, diagnosis, treatment, research, and teaching.

The “OECI Oncology Days 2022” covers a series of current topics in oncology. The three conference days include: a first day dedicated to updating the activities of the OECI working groups (WG); a second day focused to the Scientific Conference presenting the topic of “**Artificial intelligence: a tool in modern and future oncology**” as a resource with great potential that should be incorporated into our cancer centers; and finally, the third day will be devoted to the OECI General Assembly.

Artificial intelligence (AI), as is known, consists of a set of technologies that allow machines to perceive, understand, act and learn in the same way that the human mind does through processes such as machine learning. and deep learning. The application of AI in the field of Oncology has great potential, not only in making diagnoses or predictions of the evolution of the disease with greater precision, but also in identifying more personalized treatments and optimizing the hospital management. During the “OECI Oncology Days 2022” we will have international experts who have relied on these tools for clinical decision making, and they will show us examples of AI applications in the field of medical imaging and genomic data, and its impact on the prognosis and therapeutic approach of the cancer patient. We will end the day by addressing the future challenges and the limitations that AI also poses for us.

Valencia, the third largest city in Spain for its population, is a city in economic and social expansion, recognized for being welcoming and fully open to the European Community and the millions of visitors who annually enjoy our Mediterranean climate and culture.

It is an honor to welcome you to our city. We hope that Valencia is a pleasant and friendly place for the celebration of the “OECI Oncology Days 2022”.

Antonio Llombart Bosch
President IVO Foundation



Manuel Llombart Fuyertes
General Director IVO Foundation



In 1974, Antonio Llombart Rodríguez, professor of Histology and Pathology at the Medical School of the University of Valencia, and Tomás Trenor Azcárraga, 2nd Marquis of Turia and Mayor of Valencia in the 1950s, promoted together with the Spanish Association Against Cancer in Valencia (AECC), the construction in Valencia city of “a non-profit institute specialized in the treatment of tumor diseases”.

Two years later, on December 1st, 1976, her Majesty Queen Sofia inaugurated the main building of the Fundación Instituto Valenciano de Oncología (IVO). An initiative that had been born in an altruistic and disinterested way, aimed at cancer patients care in Valencia, had become a reality.

At that time, the hospital center had a Radiotherapy Service, a Tumor Polyclinic, a Laboratory Area, a Home-Care Service, hospitalization floors and two Operating Rooms. All this housed in a building with a peculiar architectural design, and of 3,000 m². Nowadays, baptized as “Antonio Llombart Rodríguez”, this building has become iconic and the most recognizable of the four that make up a Hospital Complex of more than 25,000 m². Additionally to these spaces, the IVO has an Early Diagnosis Unit, located outside the hospital complex, and two Radiotherapy Units outside Valencia, one in Alcoy (Alicante) and another in Cuenca (Castilla La Mancha).

Beyond its facilities, the IVO is characterized by the experience it has gained from being the first monographic cancer center open in Spain. A journey that has made up a medical team of professionals of enormous prestige in the treatment and research of oncological diseases.

The IVO's premise is to be a reference in cancer cutting edge technology. For this reason, it makes great efforts in the continuous renovation of its facilities and in staying at the forefront of treatments, incorporating the most advanced resources. Among others, the IVO has the Da Vinci Xi robot, two next generation magnetic resonance imaging equipments, one of the first digital PET-CT in the Valencian Community and a Gamma camera with SPECT-CT. In addition, it has six cutting edge linear accelerators and has recently launched a modern Clean Room that guarantees the preparation of drugs for cancer patients in optimal conditions of quality and safety.

The IVO remains firm in its original purpose, to make available a monographic cancer center of excellence to citizens. Supported by the best human team and the most innovative technology, offers a comprehensive care for cancer patients. After almost 50 years of history, the IVO constitutes a national and international referent in the treatment of oncological processes, a cancer center specialized in the multidisciplinary approach to a disease that still today continues being one of the greatest challenges of medicine.

OECI thanks the
Fundación - Instituto Valenciano de Oncología
for kindly accepting to organise the 44th Edition of the OECI Oncology Days



The OECI Board

 President Thierry Philip Paris, France	 Treasurer Manuel Llombart Fuertes Valencia, Spain
 Vice-President and Executive Secretary Giovanni Apolone Milan, Italy	 Elected Member Maja Čemažar Slovenia
 Elected Member Christian Brands Frankfurt, Germany	 Elected Member József Lövey Budapest, Hungary
 Elected Member Iwona Lugowska Poland	 Elected Member Jacqueline Stouthard The Netherlands
 Elected Member Gunnar Sæter Oslo, Norway	 OECI General Manager Claudio Lombardo Brussels, Belgium - Genoa, Italy
 OECI Central Office Guy Storme Brussels, Belgium	

Accreditation and Designation Programme


 A&D Chair Jean-Benoit Burrier Institut Jules Bordet Brussels, Belgium	 ACCREDITATION AND DESIGNATION PROGRAMME	 OECI COMPREHENSIVE CANCER NETWORK	 A&D Director Simon Oberst OECI Bornholm, Denmark
--	--	--	---

Working Groups

 Biobanks and Molecular Pathobiology Giorgio Stanta Trieste, Italy	 Cancer Outcomes Research Cinzia Brunelli Milan, Italy
 Cancer Economics and Benchmarking Wim H. van Harten Amsterdam, The Netherlands	 Collaboration for Good Practices with Patients Dominique de Valeriola Brussels, Belgium

OECI2022 ONCOLOGY DAYS

The OECI Network



OECI-EEIG Central Office - c/o Fondation Universitaire - 11, Rue d'Egmont
Phone: +32 2 512 0146, B-1000 Brussels, Belgium
www.oeci.eu oeci@oeci.eu

The OECI Membership

Austria

- Comprehensive Cancer Center Vienna, Vienna

Belgium

- ★ Institut Jules Bordet (IJB), Brussels
- ★ AZ Groeninge, Kortrijk
- Oncologisch Centrum UZBrussel, Brussels
- Institut Roi Albert II Cliniques universitaires Saint-Luc, Brussels

Chile

- ★ Instituto Oncológico Fundación Arturo López Pérez (FALP), Santiago

Colombia

- Instituto Nacional de Cancerología ESE, Bogotá

Croatia

- Klinika za tumore Klinički bolnički centar Sestre milosrdnice, Zagreb

Czech Republic

- ★ Masarykův onkologický ústav, Brno
- Fakultní nemocnice v Motole, Prague
- Institut biostatistiky a analýz Lékařská fakulta Masarykovy univerzity, Brno

Denmark

- ★ Vejle Sygehus, Patienternes Kræftsygehus en del af Sygehus Lillebælt, Vejle
- Kræftens Bekæmpelse Center for Kræftforskning, Copenhagen

Estonia

- ★ Sihtasutus Tartu Ülikooli Kliinikum, Tartu
- North Estonia Medical Centre, Tallin
- AS Ida-Tallinna Keskhaigla, Tallin

Finland

- ★ HUS Syöpäkeskus Helsingin Yliopistollinen Sairaala, Helsinki
- ★ TYKS Syöpäkeskus Turun Yliopistollinen Sairaala, Turku
- ★ TAYS Syöpäkeskus Tampereen Yliopistollinen Sairaala, Tampere
- ★ KYS Syövänhoitokeskus Kuopion Yliopistollinen Sairaala, Kuopio
- ★ OYS Oulun Yliopistollinen Sairaala, Oulu

France

- Association Toulousaine de Oncologie Publique (ATOP), Toulouse
- ★ Centre Léon Bérard, Lyon
- ★ Institut Curie, Paris
- ★ Institut Paoli – Calmettes, Marseille
- ★ Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse
- ★ Centre François Baclesse, Caen
- ★ APHP-CARPEM Institute, Paris
- ★ Assistance Publique - Hôpitaux de Paris Institut Universitaire de Cancérologie APHP. Sorbonne Université, Paris

- ★ Institut de Cancérologie de l'Ouest (ICO), Angers - Saint Herblain
- ★ Centre Henri Becquerel, Rouen
- ★ Centre de lutte contre le cancer Eugène Marquis, Rennes
- Gustave Roussy, Villejuif
- ICANS Institut de cancérologie Strasbourg Europe, Strasbourg
- Centre Jean Perrin, Clermont-Ferrand
- Institut du Cancer de Montpellier (ICM), Montpellier
- Institut Godinot, Reims
- Centre de Lutte Contre le Cancer Georges-François Leclerc, Dijon
- Cancer Institute AP-HP. Nord - Université Paris Cité, Paris
- Institut Sainte Catherine, Avignon

Germany

- Deutsches Krebsforschungszentrum (DKFZ), Heidelberg
- Nationales Centrum für Tumorerkrankungen Dresden NCT/UCC, Dresden
- Charité Comprehensive Cancer Center, Berlin
- Universitäres Centrum für Tumorerkrankungen (UCT), Frankfurt

Hungary

- ★ Országos Onkológiai Intézet, Budapest
- Országos Korányi TBC és Pulmonológiai Intézet, Budapest

Ireland

- ★ Trinity St. James's Cancer Institute, Dublin
- ★ Beaumont RCSI Cancer Centre, Dublin
- ★ Saolta University Cancer Network, Galway University Hospitals, Galway

Italy

- ★ Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano
- ★ IRCCS Ospedale Policlinico San Martino, Genova
- ★ Istituto Europeo di Oncologia, Milano
- ★ Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano
- ★ Istituto Nazionale Tumori Regina Elena, Roma
- ★ Istituto Oncologico Veneto IRCCS-IOV, Padova
- ★ IRCCS Istituto Clinico Humanitas, Rozzano (Milano)
- ★ Istituto Nazionale Tumori IRCCS "Fondazione G.Pascale" (INT-Pascale), Napoli
- ★ Azienda Unità Sanitaria Locale di Reggio Emilia - IRCCS Istituto in Tecnologie Avanzate e Modelli Assistenziali in Oncologia, Reggio Emilia
- ★ Istituto di Candiolo FPO-IRCCS, Candiolo (Torino)

- ★ Istituto Tumori Giovanni Paolo II, Istituto di Ricovero e Cura a Carattere Scientifico, Bari
- ★ IRCCS, Centro di Riferimento Oncologico della Basilicata (CROB), Rionero in Vulture (Potenza)
- ★ Ospedale San Raffaele (OSR), Milano
- ★ Istituto Oncologico del Mediterraneo s.p.a. (IOM), Viagrande (Catania)
- ★ IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella (Verona)
- IFOM ETS – the AIRC Institute of Molecular Oncology, Milano
- IRCCS Istituto Romagnolo per lo Studio dei Tumori «Dino Amadori» IRST s.r.l., Meldola (Forlì-Cesena)
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
- IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milano
- Istituto Dermatologico San Gallicano, Roma
- Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia

Jordan

- King Hussein Cancer Center, Amman

Lithuania

- ★ National Cancer Institute, Vilnius

Norway

- ★ Oslo Universitetssykehus (OUS), Oslo

Poland

- Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw
- Wielkopolskie Centrum Onkologii, Poznań

Portugal

- ★ Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E. (IPO-Porto), Porto
- ★ Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E. (IPO-Lisboa), Lisbon
- ★ Instituto Português de Oncologia de Coimbra Francisco Gentil, E.P.E. (IPO-Coimbra), Coimbra

Romania

- ★ The "Prof. Dr. Ion Chiricută" Institute of Oncology (IOCN), Cluj-Napoca
- SC RTC Radiology Therapeutic Center Amethyst Radiotherapy, Otopeni

Russia Federation

- Tatarstan Cancer Center "TCC", Kazan
- N.N. Blokhin Russian Cancer Research Centre, Moscow
- National Medical Research Radiological Centre (NMRRC), Moscow

Serbia

- Oncology Institute of Vojvodina, Sremska Kamenica

Slovakia

- Biomedicinske centrum Slovenskej akademie vied, Bratislava

Slovenia

- ★ Onkološki Inštitut Ljubljana, Ljubljana

Spain

- ★ Fundación Instituto Valenciano de Oncología IVO, Valencia
- ★ Vall d'Hebron Barcelona Campus Hospitalari, Barcelona
- Institut Català d'Oncologia ICO, L'Hospitalet de Llobregat (Barcelona)

Sweden

- ★ Karolinska Institute and University Hospital, Stockholm
- ★ Skånes Universitetssjukhus, Lund
- ★ Sahlgrenska University Hospital, Göteborg
- Uppsala University Hospital, Uppsala
- Norrlands Universitetssjukhus, Umeå

Switzerland

- Comprehensive Cancer Center Zürich (CCCZ), Zürich

Tanzania

- The Aga Khan Hospital, Dar es Salaam

The Netherlands

- ★ Netherlands Cancer Institute, Amsterdam
- ★ Maastricht University Medical Centre+, Maastricht
- ★ University Medical Center Groningen Comprehensive Cancer Center (UMCG-CCC), Groningen
- ★ OncoZON Cancer Network, Maastricht
- Erasmus MC Cancer Institute, Rotterdam
- IKNL Integraal Kankercentrum Nederland, Utrecht
- Radboudumc Centrum voor Oncologie, Nijmegen
- Rijnstate, Arnhem

Turkey

- ★ Anadolu Sağlık Merkezi, Kocaeli
- Dokuz Eylül Üniversitesi Onkoloji Enstitüsü, Izmir

Ukraine

- RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of National Academy of Sciences of Ukraine (IEPOR), Kyiv

United Kingdom

- ★ The Christie NHS Foundation Trust, Manchester
- ★ Cancer Research UK Cambridge Centre, Cambridge
- King's Health Partners Integrated Cancer Centre, London

Viet Nam

- Bệnh viện K Viet Nam National Cancer Hospital, Hanoi

Whole Programme - Timetable

Whole Programme - Timetable

	14 June 2022	15 June 2022		
MORNING		<p>Accreditation and Designation Session Striving for excellence in Comprehensive Cancer Care, Research and Education</p> <p>Part I 8.30 - 10.30</p> <p>10.30 - 11.00 Coffee Break</p> <p>Part II 11.00 - 13.00</p>		
		Lunch		
AFTERNOON	<p>OECI Board & Extended Board meeting 15.00 - 19.00</p> <p><i>Restricted to Board & Extended Board Members</i></p>	<p>Cancer Outcomes Research WG Session 14.00 - 16.00</p> <p>16.00-16.30 Coffee Break</p> <p>Biobanks and Molecular Pathobiology WG Session 16.30 - 18.30</p>	<p>Cancer Economics and Benchmarking WG Session 14.00 - 16.00</p> <p>16.00-16.30 Coffee Break</p> <p>Collaboration for Good Practices with Patients WG Session 16.30 - 18.30</p>	<p>A&D auditors' education and discussion seminar 14.00 - 16.00</p>
		<p>A&D Board meeting 16.30 - 18.30</p>		
EVENING	Board Dinner	Dinner Hotel Primus Restaurant		

	16 June 2022	17 June 2022		
MORNING	<p>Scientific Conference ARTIFICIAL INTELLIGENCE: a tool in modern and future oncology</p> <p>Session I AI in diagnostic procedures 10.00 - 11.00</p> <p>11.00 - 11.30 Coffee Break</p> <p>Session II AI in clinical outcomes prediction 11.30 - 13.00</p>	<p>OECI General Assembly 2022 8.00 - 13.00</p> <p>Session 1 Administrative and financial matters Coffee Break</p> <p>Session 2 The OECI European Cancer Mission, the A&D Programme and the WGs</p> <p><i>Restricted to OECI Member Legal Representatives or their Delegates</i></p>		MORNING
	<p>Cancer Economics and Benchmarking WG planning meeting 10.00 - 12.00</p>			
	Lunch			
AFTERNOON	<p>Scientific Conference ARTIFICIAL INTELLIGENCE: a tool in modern and future oncology</p> <p>Session III AI future directions 14.00 - 15.45</p> <p>15.45-16.15 Coffee Break</p> <p>Session IV Applications of AI in Oncology 16.15 - 18.30</p>			AFTERNOON
EVENING	<p>OECI Gala Dinner and Ceremony for the delivery of the OECI A&D certificates July 2019 - June 2022 The Palau de les Arts Reina Sofia (Bus Transfer at 19.30)</p>			EVENING

Accreditation and Designation Session

June 15th
Hotel Primus

Striving for excellence in Comprehensive Cancer Care, Research and Education

Room:
Opera

- 08.30 **The OECI Quality and Accreditation Programme**
Introduction and overall state of play of the Quality and Accreditation Programme
Simon Oberst
- 08.50 **OECI Excellent Practices: the aim of the project**
Chair: Jean-Benoit Burrion
- 09.00 **Examples of Excellent Practices from the OECI Quality Network**
- **Marseille – Recognising the expertise of patients**
Martine Bouyssie
 - **Vejle – Patient Pathways**
Dorthe Kronborg
 - **NKI – Induction and on boarding programme**
Suzanne Verver
 - **Cambridge – Research Programme Structure**
Richard Gilbertson (video recording)
 - **Oslo – Translational Research and Innovation**
Kjetil Taskén
- 09.50 **Questions and Answers**
- 10.05 **Cancer Nursing within OECI Cancer Centres**
Chair: Yvonne Wengstrom
- 10.05 **Examples from OECI Centres**
- **Karolinska Institute – the Contact Nurse**
Yvonne Wengstrom
 - **AZ Groeninge – Co-ordinating interdisciplinary care**
Annelies Courtens
 - **AP-HP Paris CARPEM – Team-building across a Centre**
Valérie Quevieux
- 10.35 **Initiatives in Oncology Nursing from EONS**
Johan de Munter
- 10.50 *Discussion (10 minutes)*

Accreditation and Designation Session

June 15th
Hotel Primus

Room:
Opera

- 11.00 *Coffee Break*
- 11.20 **Comprehensive Cancer Infrastructures – the European Context and OECI involvement**
Chair: Simon Oberst
- 11.30 **Comprehensive Cancer Centres reaching out in networks, example of Frankfurt**
Christian Brandts
- 11.45 **Forming a Comprehensive Cancer Centre in a University Hospital – example of AP-HP Paris CARPEM**
Pierre Laurent-Puig
- 12.00 **Introduction to EU Actions on Cancer**
Matthias Schuppe (video recording)
- 12.15 **Joint Action on the Creation of a Network of Comprehensive Cancer Centres**
Tit Albrecht
- 12.30 **Round Table: Perspectives from the Cancer Mission Board and Sub-Group on Cancer “Opportunities and Challenges”**
- Panelists:*
- *Marcis Leja*
 - *Mef Nilbert*
 - *Giovanni Apolone*
- 12.55 **Closing remarks**
Simon Oberst

Cancer Outcomes Research WG Session

June 15th
Hotel Primus

A step forward patient reported outcome OMICs

Chairperson: *Giovanni Apolone*

Room:
Fenice + Bolshoi

“PROMs and PREMs are part of the broader chapter of the health-related quality of life (HR-QoL) assessment. For years, several and standardized tools have been available, widely used in clinical practice and research protocols. A lot of evidence is available on their validity and reproducibility and about what are the factors that influence the feasibility in the two areas but their added value is still open when used in the context of the new scenarios where the key factors are data sharing and integration, big data and artificial intelligence”

- 14.00 **Introduction: HRQOL, PROMs and PREMs: what are we talking about**
Giovanni Apolone
- 14.20 **HRQOL in monitoring the quality of health care interventions in Europe: the point of view of patient advocate associations**
Bettina Ryll
- 14.40 **PROMs in routine clinical practice : What evidence do we have on the impact of routine use of HRQOL tools on the patient care**
Cinzia Brunelli
- 15.00 **PROMs in clinical research: the EORTC experience**
Jamme Musoro
- 15.20 **PROMs and AI & digital therapeutics: are we ready for that?**
Samantha Cruz Rivera
- 15.40 **The role of OECI in EU funding on HRQOL calls in the Cancer Mission**
Augusto Caraceni

Cancer Economics and Benchmarking WGs Session

June 15th
Hotel Primus

Costs and Consequences of Personalized Cancer Treatment

Chairperson: *Win van Harten*

Room:
Opera

Personalized and (combined) targeted treatment come with considerable costs, challenging the financial sustainability of health systems. We present findings from a survey on combined targeted treatments in 10 EU countries and from an economic experiment on transparency in price negotiations. Currently there is little data on the socio economic consequences (SEC) of cancer and it's treatment. for patients. We present data from the OECI on shot project survey on this topic in 15 EU countries. There is a need for consensus on valid instruments to asses SEC. An interim report from- and discussion with the OECI taskforce on socioeconomic consequences of cancer ends this session.

- 14.00 **Introduction**
Wim van Harten
- 14.10 **Developments in costly Cancer treatments**
Nils Wilking
- 14.30 **Targeted treatment combinations**
James O'Mahony
- 14.45 **Transparency as a solution to high prices**
Nora Franzen
- 15.00 **Socio Economic Consequences of Cancer**
Julie Vancoppenolle
- 15.20 **Methods and Instruments in Analysis of Socio Economic Consequences**
Michael Schlander
- 15.40 **Discussion and consensus**

Biobanks and Molecular Pathobiology WG Session

June 15th
Hotel Primus

Room:
Fenice + Bolshoi

Molecular Pathology Standardization

Chairperson: *Giorgio Stanta*

Today one of the major problem in oncology diagnostics is that the molecular analyses are not standardized to perform reproducible and exchangeable molecular diagnostic analysis. This is even more pressing because of the continuously increased use of prognostic and predictive biomarkers, directly related to treatment choices and the interpretation of results of diagnostics and clinical research molecular analysis is increasingly complex.

16.30 **Introduction “Molecular Pathology Standardization”**
Giorgio Stanta

16.45 **Tissue treatment and preservation**
Olli Carpen

17.05 **DNA preservation and analysis standardization**
Gerald Hoefler

17.25 **RNA preservation and analysis standardization**
Serena Bonin

17.45 **Proteins preservation and analysis standardization**
Karl Becker

18.05 **General discussion**

Collaboration for Good Practices with Patients WG Session

June 15th
Hotel Primus

Room:
Opera

Moving from Patient Involvement to Co-Creation with Patients

Chairperson: *Dominique de Valeriola*

OECI cancer centers are collaborating with patients and their close ones to enhance the quality of care and research. Indeed, patient experience is improved when patient perspectives are taken into account in the redesign of cancer centers activities. In this session, we will give an update on the recent changes in patient

16.30 **Introduction**
Dominique de Valeriola

16.45 **Patient Involvement 2.0: the Karolinska experience**
Eva Jolly and Yvonne Wengstrom

17.05 **Canadian experience of patient partnership in quality improvement**
Marie-Pascale Pomey

17.25 **Co-creation approach at Institut Jules Bordet with patients-experts, artists and professionals**
Patrick Miqueu

17.45 **The point of view of co-creation from a patient organization**
Bettina Ryll

18.05 **Discussion**
A&D auditors' education and discussion seminar

14.00
16.00

Link to the Webinar:

<https://oncologydaysvalencia2022.onsitevents.com/>

The workshop aims to:

- Provide a forum to meet with other OECI auditors and share experiences
- Share the results of the recent Auditor Survey and hear your reflections on this
- Optimising the ways of working and duties of auditors
- Discuss possibilities to support and develop OECI's services to the auditors

June 15th
Hotel Primus

Room:
Metropolitan

Scientific Conference

June 16th

Hotel Primus

Room:
Opera

ARTIFICIAL INTELLIGENCE: a tool in modern and future oncology

09.00 **Opening and welcome of the authorities**
Antonio Llombart Bosch

Opening lecture

Comprehensive cancer centers in Europe: OECI and European alignment
Thierry Philip (30')

10.00 **SESSION I**

AI in diagnostic procedures

Chairs: Rui Henrique and Giorgio Stanta

- **Artificial intelligence and computational pathology**
Håvard Danielsen
- **Artificial intelligence application in cancer diagnostics**
Regina Beets
- **Radiomics in Oncology: A Practical Guide**
Angel Alberich Bayarri

Panel discussion (15')

11.00 Coffee Break

11.30 **SESSION II**

AI in clinical outcome prediction

Chairs: Marco Pierotti and Iwona Lugowska

- **AI and tumor molecular profiling**
José Antonio López-Guerrero
- **May AI replace classic statistical approaches to predict clinical outcomes?**
Jan Poleszczuk
- **Deep learning NMR and outcomes prediction**
Leonor Cerdá-Alberich
- **AI in computational biology: tackling the difficulty of integrating complex datastreams from different diagnostic**
Florian Markowetz (video recording)

Panel discussion (15')

13.00 Lunch

Scientific Conference

June 16th

Hotel Primus

Room:
Opera

ARTIFICIAL INTELLIGENCE: a tool in modern and future oncology

14.00 **Key Lecture: BIG DATA & AI**
Alfonso Valencia (30')

14.30 **SESSION III**

AI Future Directions

Chairs: Giovanni Apolone and Ignacio Galve

- **A new vision for collaborative RWD studies**
Gennaro Ciliberto
- **AI and Big Data in Cancer Outcome Research**
Xosé Fernandez
- **Big Data: may pharma companies and academy be allied?**
Woolmore Ashley
- **Large-scale predictive model development and validation using data standardised to the OMOP Common Data Model**
Peter Rijnbeek

Panel discussion (15')

15.45 Coffee Break

16.15 **SESSION IV**

Applications of AI in Oncology

Chairs: Antonio Llombart Cussac and Maja Čemažar

- **Experiences of AI in cancer surgery**
Ibrahim Edhemovic
- **AI in Radiation Oncology**
József Lövey
- **AI in drug development**
Andreas Bender
- **Drug repurposing in oncology**
Ciro Mercurio

Panel discussion (15')

17.30 **Key Lecture: The challenge of AI for OECI Members**
Giovanni Apolone (30')

18.00 **Closing remarks**

- 08.00 **Registration**
- 08.15 **Opening: A message from the Director of the RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of NAS of Ukraine – Kyiv**
Prof. Vasyl Checkhun
- 08.30 **General Assembly Constitution, welcome and approval of the Agenda**
Thierry Philip
- 08.45 **Session 1**
Administrative and financial matters
Chairperson: Thierry Philip
- Point 1: Approval of May 26th - 2021 General Assembly Minutes**
(vote requested - decision to be taken by simple majority of the OECI Full Members present or represented)
Thierry Philip
- Point 2: Approval of the Financial Statement 2021 and discharge to the Board**
(vote requested - decision to be taken by simple majority of the OECI Full Members present or represented)
Manuel Llombart Fuertes
- Point 3: OECI 2022 and 2023 Provisional Budgets**
(vote requested - decision to be taken by simple majority of the OECI Full Members present or represented –only for Provisional 2022)
Manuel Llombart Fuertes
- Point 4: OECI Board composition for the coming years**
(vote requested - decision to be taken by simple majority of the OECI Full Members present or represented)
Thierry Philip
- Point 5: Co-opted Members to the Board - update**
(vote not requested)
Thierry Philip

- Point 6: New applications, Membership modification and payment exemption for some Members**
(vote requested for full membership - decision to be taken by unanimity of the OECI Full Members present or represented; for associate membership - decision to be taken by simple majority of the OECI Full Members present or represented)
Claudio Lombardo
- Point 7: Oncology Days Paris 2023, and for the coming years**
Thierry Philip
- 11.00 *Coffee Break*
- 11.15 **Session 2**
OECI participation to EC Programmes, the A&D Programme, WGs
Chairperson: Thierry Philip
- OECI participation to the Cancer Mission and to the European Beating Cancer Plan**
Giovanni Apolone
- Accreditation & Designation Programme**
Simon Oberst
- Collaboration for good practices with patients WG**
Dominique de Valeriola
- Biobanks and molecular pathobiology WG**
Giorgio Stanta
- Health economics and benchmarking WG**
Wim H. van Harten
- Cancer outcomes research WG**
Cinzia Brunelli
- 13.00 **Closure of the 2022 General Assembly**

List of invited speakers and moderators

Albreht Tit

National Institute of Public Health, Ljubljana, Slovenia

Apolone Giovanni

Fondazione Istituto Nazionale Tumori Milan, Italy

Bayarri Angel Alberich

Polytechnics University of Valencia, Spain

Becker Karl

Technical University of Munich, Germany

Beets Regina

Netherlands Cancer Institutes, Amsterdam, The Netherlands

Bender Andreas

University of Cambridge, United Kingdom

Bonin Serena

DSM-Università di Trieste, Italy

Bouyssie Martine

Institut Paoli Calmettes, Marseille, France

Brandts Christian

University Cancer Center Frankfurt, Germany

Brunelli Cinzia

Fondazione Istituto Nazionale Tumori Milan, Italy

Burrión Jean-Benoit

Institut Jules Bordet, Brussels, Belgium

Caraceni Augusto

Fondazione Istituto Nazionale Tumori Milan, Italy

Carpén Olli

University of Helsinki, Finland

Cemažar Maja

Institute of Oncology, Ljubljana, Slovenia

Cerdá-Alberich Leonor

Polytechnic and University Hospital La Fe, Valencia, Spain

Checkun Vasyl

RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of National Academy of Sciences of Ukraine (IEPOR), Kyiv, Ukraine

Ciliberto Gennaro

Istituto Regina Elena Roma, Italy

Courtens Annelies

Kortrijk Cancer Centre AZ Groeninge, Belgium

Cruz Rivera Samantha

Institute of Applied Health Research, University of Birmingham, United Kingdom

Danielsen Håvard

Oslo University Hospital CCC, Norway

de Munter Johana

European Oncology Nursing Society (EONS), Brussels, Belgium

de Valeriola Dominique

Institut Jules Bordet, Brussels, Belgium

Ethemovic Ibrahim

Institute of Oncology Ljubljana, Slovenia

Fernandez Xosé

Institut Curie Paris, France

Franzen Nora

Netherlands Cancer Institutes, Amsterdam, The Netherlands

Galve Castillo Ignacio

Fundación Instituto Valenciano de Oncología, Valencia, Spain

Gilbertson Richard J.

Cambridge Cancer Centre, United Kingdom

Henrique Rui

IPO Porto, Portugal

Hoefler Gerald

University of Graz, Austria

Jolly Eva

Karolinska Institute, Stockholm, Sweden

Kronborg Dorte

Vejle Cancer Centre, Denmark

Leja Marcis

University of Latvia, Riga, Latvia

Llombart Cussac Antonio

Arnau de Vilanova Hospital Valencia, Spain

List of invited speakers and moderators

Llombart Fuertes Manuel

Fundación Instituto Valenciano de Oncología, Valencia, Spain

Llombart Bosch Antonio

Fundación Instituto Valenciano de Oncología, Valencia, Spain

Lombardo Claudio

OECI Organisation of European Cancer Institutes (OECI), Brussels, Belgium

Lopez-Guerrero José Antonio

Fundación Instituto Valenciano de Oncología, Valencia, Spain

Lugowska Iwona

Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland

Markowitz Florian

Cancer Research UK Cambridge Institute, United Kingdom

Mercurio Ciro

IFOM Milan, Italy

Miqueu Patrick

Institut Jules Bordet, Brussels, Belgium

Musoro Jammbe

EORTC, Brussels, Belgium

Nilbert Mef

Danish Cancer Society, Copenhagen, Denmark

O'Mahony James

Trinity College Dublin, Ireland

Oberst Simon

Organisation of European Cancer Institutes (OECI), Brussels, Belgium

Philip Thierry

Institut Curie Paris, France

Pierotti Marco

IFOM – Cogentech Milan, Italy

Poleszczuk Jan

Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland

Pomey Marie-Pascale

Université de Montréal, Canada

Quevieux Valérie

APHP – CARPEM, Paris, France

Rijnbeek Peter

Health Data Science Erasmus, Rotterdam, The Netherlands

Ryll Bettina

Melanoma Patient Network Europe, Stockholm, Sweden

Schlender Michael

German Cancer Research Center, Heidelberg, Germany

Schuppe Matthias

European Commission DG SANTE, Luxembourg

Stanta Giorgio

Università degli Studi di Trieste, Italy

Taskén Kjetil

Oslo University Hospital, Norway

Valencia Alfonso

Computational Biology Life Sciences Group Barcelona, Spain

van Harten Wim H.

Rijnstate Hospital Arnhem, The Netherlands

Vancoppenolle Julie

Netherlands Cancer Institutes, Amsterdam, The Netherlands

Verver Suzanne

Netherlands Cancer Institutes, Amsterdam, The Netherlands

Wengstrom Yvonne

Karolinska Institute, Stockholm, Sweden

Wilking Nils

Karolinska Institute, Stockholm, Sweden

Woolmore Ashley

IQVIA, Paris, France



THE OEI 2022 SCIENTIFIC COMMITTEE

Presidents

Thierry Philip and Antonio Llombart Bosch

Members

Giovanni Apolone, Maja Cemažar, Christian Brandts, Dominique de Valeriola, Manuel Llombart Fuertes, Claudio Lombardo, Jozsef Lovey, Iwona Lugowska, Simon Oberst, Gunnar Sæater, Giorgio Stanta, Jaqueline Stouthard, Wim van Harten

THE OEI 2022 NATIONAL SCIENTIFIC AND ORGANISING COMMITTEE

President

Antonio Llombart Bosch and Manuel Llombart Fuertes

Members

José Antonio López-Guerrero, Tomás Quirós

THE OEI 2022 ONCOLOGY DAYS SECRETARIATS

OEI Liaison Office:

Giorgia Pesce, Patrizia Sommella, Roxana Plesoianu, Daniela Garbarino

Cevents – Valencia:

Marina Rivilla marina@cevents.es

Sheila López sheila@cevents.es

Cevents

IVO – Valencia:

Belén Bolás bbolas@fivo.es

Paris: Anna Fackeure

Milan: Eleonora Di Palo

OEI 2022 ONCOLOGY DAYS COORDINATING OFFICE

Claudio Lombardo - OEI General Manager

Phone +32 2 512 01 46

oei@oei.eu - www.oei.eu

In collaboration with

